Imunon (IMNN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 May, 2026Executive summary
Annual meeting scheduled for June 16, 2026, will be held virtually to enhance accessibility and reduce costs.
Four key proposals: election of two Class I directors, ratification of auditor, advisory vote on executive compensation, and amendment to the 2018 Stock Incentive Plan.
Record date for voting is April 17, 2026, with 3,983,342 shares outstanding.
Proxy materials and annual report are available online and by request.
Voting matters and shareholder proposals
Proposal 1: Elect two Class I Directors (Frederick J. Fritz and Christine A. Pellizzari) for terms expiring in 2029.
Proposal 2: Ratify WithumSmith + Brown PC as independent auditor for fiscal year 2026.
Proposal 3: Advisory vote to approve 2025 executive compensation.
Proposal 4: Approve amendment to 2018 Stock Incentive Plan, increasing share limit by 1,000,000 shares.
Shareholders may submit proposals for the 2027 annual meeting by specified deadlines.
Board of directors and corporate governance
Board consists of six members divided into three staggered classes; four are independent.
Committees include Audit, Compensation, Nominating and Governance, and Science and Technology.
Board diversity: 2 female, 4 male directors; all are White.
Annual review of board independence and director qualifications; stock ownership guidelines in place.
Latest events from Imunon
- IMNN-001 Phase 3 enrollment outpaces plan; $10M financing supports trials amid funding risks.IMNN
Q2 2026 - IMNN-001 demonstrated a 13-month survival gain in ovarian cancer, with phase III now enrolling.IMNN
Life Sciences Investor Forum - All proposals passed, clinical milestones advanced, and financial strategy remains strong.IMNN
AGM 2026 - IL-12 immunotherapy shows 14.7-month survival gain in ovarian cancer, advancing in Phase 3.IMNN
Life Sciences Virtual Investor Forum - IMNN-001 showed strong survival benefit; Phase 3 enrollment advances, but cash concerns persist.IMNN
Q1 2026 - Phase II survival benefit accelerates Phase III enrollment and financial improvements.IMNN
Q4 2025 - Positive Phase II data, new funding, and reduced losses support pivotal trial plans.IMNN
Q2 2024 - IMNN-001 improved survival and surgical outcomes in advanced ovarian cancer, supporting Phase 3 plans.IMNN
Study Result - IMNN-001 delivered significant survival gains in ovarian cancer, with Phase 3 launch and funding efforts underway.IMNN
Q4 2024